BACKGROUND: Millions of individuals being treated for human immunodeficiency virus (HIV) live in malaria-endemic areas, but the effects of these treatments on malaria transmission are unknown. While drugs like HIV protease inhibitors (PIs) and trimethoprim-sulfamethoxazole (TMP-SMX) have known activity against parasites during liver or asexual blood stages, their effects on transmission stages require further study. METHODS: The HIV PIs lopinavir and saquinavir, the nonnucleoside reverse-transcriptase inhibitor nevirapine, and the antibiotic TMP-SMX were assessed for activity against Plasmodium falciparum transmission stages. The alamarBlue assay was used to determine the effects of drugs on gametocyte viability, and exflagellation was assessed to determine the effects of drugs on gametocyte maturation. The effects of drug on transmission were assessed by calculating the mosquito oocyst count as a marker for infectivity, using standard membrane feeding assays. RESULTS: Lopinavir and saquinavir have gametocytocidal and transmission blocking activities at or approaching clinically relevant treatment levels, while nevirapine does not. TMP-SMX is not gametocytocidal, but at prophylactic levels it blocks transmission. CONCLUSIONS: Specific HIV treatments have gametocyte killing and transmission-blocking effects. Clinical studies are warranted to evaluate these findings and their potential impact on eradication efforts.
BACKGROUND: Millions of individuals being treated for human immunodeficiency virus (HIV) live in malaria-endemic areas, but the effects of these treatments on malaria transmission are unknown. While drugs like HIV protease inhibitors (PIs) and trimethoprim-sulfamethoxazole (TMP-SMX) have known activity against parasites during liver or asexual blood stages, their effects on transmission stages require further study. METHODS: The HIV PIs lopinavir and saquinavir, the nonnucleoside reverse-transcriptase inhibitor nevirapine, and the antibiotic TMP-SMX were assessed for activity against Plasmodium falciparum transmission stages. The alamarBlue assay was used to determine the effects of drugs on gametocyte viability, and exflagellation was assessed to determine the effects of drugs on gametocyte maturation. The effects of drug on transmission were assessed by calculating the mosquito oocyst count as a marker for infectivity, using standard membrane feeding assays. RESULTS:Lopinavir and saquinavir have gametocytocidal and transmission blocking activities at or approaching clinically relevant treatment levels, while nevirapine does not. TMP-SMX is not gametocytocidal, but at prophylactic levels it blocks transmission. CONCLUSIONS: Specific HIV treatments have gametocyte killing and transmission-blocking effects. Clinical studies are warranted to evaluate these findings and their potential impact on eradication efforts.
Authors: Francesco Silvestrini; Edwin Lasonder; Anna Olivieri; Grazia Camarda; Ben van Schaijk; Massimo Sanchez; Sumera Younis Younis; Robert Sauerwein; Pietro Alano Journal: Mol Cell Proteomics Date: 2010-03-22 Impact factor: 5.911
Authors: Jason A Young; Quinton L Fivelman; Peter L Blair; Patricia de la Vega; Karine G Le Roch; Yingyao Zhou; Daniel J Carucci; David A Baker; Elizabeth A Winzeler Journal: Mol Biochem Parasitol Date: 2005-09 Impact factor: 1.759
Authors: Samuel S Malamba; Jonathan Mermin; Arthur Reingold; John R Lule; Robert Downing; Ray Ransom; Aminah Kigozi; Ben M Hunt; Alan Hubbard; Philip J Rosenthal; Grant Dorsey Journal: Am J Trop Med Hyg Date: 2006-09 Impact factor: 2.345
Authors: Sunil Parikh; Jiri Gut; Eva Istvan; Daniel E Goldberg; Diane V Havlir; Philip J Rosenthal Journal: Antimicrob Agents Chemother Date: 2005-07 Impact factor: 5.191
Authors: Aminatou Kone; Marga van de Vegte-Bolmer; Rianne Siebelink-Stoter; Geert-Jan van Gemert; Antoine Dara; Hamidou Niangaly; Adrian Luty; Ogobara K Doumbo; Robert Sauerwein; Abdoulaye A Djimde Journal: Int J Parasitol Date: 2010-06-02 Impact factor: 3.981
Authors: Yimin Wu; Ruth D Ellis; Donna Shaffer; Erica Fontes; Elissa M Malkin; Siddhartha Mahanty; Michael P Fay; David Narum; Kelly Rausch; Aaron P Miles; Joan Aebig; Andrew Orcutt; Olga Muratova; Guanhong Song; Lynn Lambert; Daming Zhu; Kazutoyo Miura; Carole Long; Allan Saul; Louis H Miller; Anna P Durbin Journal: PLoS One Date: 2008-07-09 Impact factor: 3.240
Authors: Julien Duez; John P Holleran; Papa Alioune Ndour; Sasdekumar Loganathan; Pascal Amireault; Olivier Français; Wassim El Nemer; Bruno Le Pioufle; Inês F Amado; Sylvie Garcia; Nathalie Chartrel; Caroline Le Van Kim; Catherine Lavazec; Vicky M Avery; Pierre A Buffet Journal: Antimicrob Agents Chemother Date: 2015-05-04 Impact factor: 5.191
Authors: Charlotte V Hobbs; Patricia De La Vega; Scott R Penzak; Jillian Van Vliet; Urszula Krzych; Photini Sinnis; William Borkowsky; Patrick E Duffy Journal: AIDS Date: 2013-06-19 Impact factor: 4.177
Authors: Christopher Schwake; Michael R Baldwin; William Bachovchin; Shreeya Hegde; James Schiemer; Carolyn Okure; Andrew E Levin; Edouard Vannier; Toshihiko Hanada; Athar H Chishti Journal: Biochem Biophys Res Commun Date: 2019-07-13 Impact factor: 3.575
Authors: Takeshi Q Tanaka; W Armand Guiguemde; David S Barnett; Maxim I Maron; Jaeki Min; Michele C Connelly; Praveen Kumar Suryadevara; R Kiplin Guy; Kim C Williamson Journal: Antimicrob Agents Chemother Date: 2014-12-15 Impact factor: 5.191
Authors: Thomas E Kraft; Christopher Armstrong; Monique R Heitmeier; Audrey R Odom; Paul W Hruz Journal: Antimicrob Agents Chemother Date: 2015-07-27 Impact factor: 5.191